Annual CFO
-$107.06 M
-$23.33 M-27.87%
31 December 2023
Summary:
Prelude Therapeutics Incorporated annual cash flow from operations is currently -$107.06 million, with the most recent change of -$23.33 million (-27.87%) on 31 December 2023. During the last 3 years, it has fallen by -$60.89 million (-131.85%). PRLD annual CFO is now -726.49% below its all-time high of -$12.95 million, reached on 31 December 2018.PRLD Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.30 M
-$4.24 M-18.38%
30 September 2024
Summary:
Prelude Therapeutics Incorporated quarterly cash flow from operations is currently -$27.30 million, with the most recent change of -$4.24 million (-18.38%) on 30 September 2024. Over the past year, it has dropped by -$1.61 million (-6.28%). PRLD quarterly CFO is now -206.63% below its all-time high of -$8.90 million, reached on 30 June 2020.PRLD Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$105.72 M
-$1.61 M-1.55%
30 September 2024
Summary:
Prelude Therapeutics Incorporated TTM cash flow from operations is currently -$105.72 million, with the most recent change of -$1.61 million (-1.55%) on 30 September 2024. Over the past year, it has increased by +$690.00 thousand (+0.65%). PRLD TTM CFO is now -965.64% below its all-time high of -$9.92 million, reached on 31 March 2020.PRLD TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRLD Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.9% | -6.3% | +0.7% |
| 3 y3 years | -131.8% | -25.4% | -45.5% |
| 5 y5 years | -726.5% | - | - |
PRLD Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -131.8% | at low | -47.8% | +14.1% | -45.5% | +2.8% |
| 5 y | 5 years | -726.5% | at low | -206.6% | +14.1% | -965.6% | +2.8% |
| alltime | all time | -726.5% | at low | -206.6% | +14.1% | -965.6% | +2.8% |
Prelude Therapeutics Incorporated Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.30 M(+18.4%) | -$105.72 M(+1.5%) |
| June 2024 | - | -$23.06 M(-27.5%) | -$104.11 M(-4.2%) |
| Mar 2024 | - | -$31.79 M(+34.8%) | -$108.72 M(+1.5%) |
| Dec 2023 | -$107.06 M(+27.9%) | -$23.58 M(-8.2%) | -$107.06 M(+0.6%) |
| Sept 2023 | - | -$25.68 M(-7.2%) | -$106.41 M(+5.2%) |
| June 2023 | - | -$27.67 M(-8.2%) | -$101.17 M(+10.0%) |
| Mar 2023 | - | -$30.13 M(+31.4%) | -$91.97 M(+9.8%) |
| Dec 2022 | -$83.73 M | -$22.93 M(+12.2%) | -$83.73 M(-3.2%) |
| Sept 2022 | - | -$20.44 M(+10.7%) | -$86.50 M(-1.5%) |
| June 2022 | - | -$18.47 M(-15.7%) | -$87.84 M(-1.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$21.89 M(-14.8%) | -$89.28 M(+6.9%) |
| Dec 2021 | -$83.53 M(+80.9%) | -$25.70 M(+18.0%) | -$83.53 M(+14.9%) |
| Sept 2021 | - | -$21.77 M(+9.4%) | -$72.68 M(+14.6%) |
| June 2021 | - | -$19.91 M(+23.3%) | -$63.41 M(+21.0%) |
| Mar 2021 | - | -$16.14 M(+8.7%) | -$52.40 M(+13.5%) |
| Dec 2020 | -$46.18 M(+79.9%) | -$14.85 M(+18.7%) | -$46.18 M(+47.4%) |
| Sept 2020 | - | -$12.51 M(+40.5%) | -$31.33 M(+66.4%) |
| June 2020 | - | -$8.90 M(-10.3%) | -$18.82 M(+89.7%) |
| Mar 2020 | - | -$9.92 M | -$9.92 M |
| Dec 2019 | -$25.66 M(+98.1%) | - | - |
| Dec 2018 | -$12.95 M | - | - |
FAQ
- What is Prelude Therapeutics Incorporated annual cash flow from operations?
- What is the all time high annual CFO for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated annual CFO year-on-year change?
- What is Prelude Therapeutics Incorporated quarterly cash flow from operations?
- What is the all time high quarterly CFO for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated quarterly CFO year-on-year change?
- What is Prelude Therapeutics Incorporated TTM cash flow from operations?
- What is the all time high TTM CFO for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated TTM CFO year-on-year change?
What is Prelude Therapeutics Incorporated annual cash flow from operations?
The current annual CFO of PRLD is -$107.06 M
What is the all time high annual CFO for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual cash flow from operations is -$12.95 M
What is Prelude Therapeutics Incorporated annual CFO year-on-year change?
Over the past year, PRLD annual cash flow from operations has changed by -$23.33 M (-27.87%)
What is Prelude Therapeutics Incorporated quarterly cash flow from operations?
The current quarterly CFO of PRLD is -$27.30 M
What is the all time high quarterly CFO for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly cash flow from operations is -$8.90 M
What is Prelude Therapeutics Incorporated quarterly CFO year-on-year change?
Over the past year, PRLD quarterly cash flow from operations has changed by -$1.61 M (-6.28%)
What is Prelude Therapeutics Incorporated TTM cash flow from operations?
The current TTM CFO of PRLD is -$105.72 M
What is the all time high TTM CFO for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high TTM cash flow from operations is -$9.92 M
What is Prelude Therapeutics Incorporated TTM CFO year-on-year change?
Over the past year, PRLD TTM cash flow from operations has changed by +$690.00 K (+0.65%)